share_log

华东医药(000963.SZ):从整体来看集采对于公司影响的高峰期已经过去

Huadong Pharmaceutical (000963.SZ): Looking at the whole, the peak period of influence of collection on the company is over

Gelonghui Finance ·  Feb 20, 2023 15:25

Gelonghui February 20 丨Huadong Pharmaceutical (000963.SZ) was surveyed on-site by the agency at 14:30-16:00 on February 15, 2023; 11:00-11:40 and 14:00-15:00 on February 16, saying that last year, the company's products such as temicophenol ester capsules, pioglitazone hydrochloride tablets, and ornidazole tablets participated and successfully won the seventh batch of centralized national drug procurement, which has now begun implementation in various provinces and cities. As the country continues to promote the normalization of centralized drug procurement, some of the company's generic drugs will still face the impact of national, provincial and municipal alliances in the future. However, looking at it as a whole, the peak period of influence of collection on the company is over. In the future, with the continuous growth of innovative business, the impact of individual variety collection will also be gradually digested, and it will not affect the trend of the company returning to the growth path.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment